The missing link: Translating cutting edge research into cutting edge cures
New York Times columnist David Bornstein posted two columns this month about the challenges facing pharma and how the Myelin Repair Foundation is fostering more open pathways between basic science and commercial drug development.
With NIH Director Francis Collins’ proposed venture for a center for translational medicine, the topic remains a high priority.
Read David Bornstein’s columns here:
